Humacyte arriva a un catalyst clinico ravvicinato: i risultati interim dello studio Phase 3 V012 nell’accesso vascolare per emodialisi saranno disponibili per la presentazione allo SVS Vascular Annual Meeting di Boston. Il punto non è solo il dato clinico, ma la possibilità di trasformare ATEV/Symvess da prodotto approvato per trauma vascolare a piattaforma con una seconda indicazione potenzialmente molto più ampia.

Deep dive completo per trader su Nurix Therapeutics, la collaborazione Roche per bexobrutideg, la piattaforma di targeted protein degradation, pipeline clinica e partnered, runway finanziario, ownership, catalizzatori, rischi e scenari che contano dopo l’annuncio dell’8 giugno.

Analisi approfondita di Enliven Therapeutics (Nasdaq: $ELVN): il candidato ELVN-001 per la leucemia mieloide cronica, i dati Phase 1 ENABLE (MMR 69%), il catalyst dell'EHA 2026 dell'11 giugno, l'avvio del Phase 3 ENABLE-2 in H2 2026 e la cassa di $452M. Report bilingue IT/EN con Health Score Merlintrader 4.0/5.

Three biotechnology and healthcare names are standing out this morning for very different reasons. Zenas BioPharma (Nasdaq: $ZBIO) is the highest-quality fundamental setup among the group because the latest news is tied to a registrational Phase 3 dataset, a peer-reviewed medical publication, a major rheumatology conference and a recently submitted Biologics License Application. Verastem Oncology (Nasdaq: $VSTM) offers the cleanest oncology headline because the company has expanded the regulatory visibility of its KRAS G12D program through an FDA Fast Track designation in non-small cell lung cancer. Edesa Biotech (Nasdaq: $EDSA) is the most speculative of the three, but it has a timely conference catalyst in acute kidney injury, an area with high mortality, limited pharmacological options and a plausible inflammatory biology angle.

A single-stock deep dive on the Phase 2b PLATEAU trial, Wegovy supply, enobosarm’s GLP-1 adjunct thesis, FDA pathway, cash runway, dilution risk, catalysts, and the real bull-bear setup behind Veru.

A deep dive into tebipenem HBr, the GSK partnership, the PIVOT-PO data package, Spero’s financial position, and the key regulatory risks heading into the June 18, 2026 PDUFA date.

Cardiff Oncology, BeyondSpring and Lantern Pharma each used the final day of ASCO 2026 to push a different small-cap oncology story: a randomized colorectal cancer signal moving toward a registrational program, a post-checkpoint lung cancer combination with long follow-up, and a biomarker-focused NSCLC dataset tied to an FDA-cleared protocol amendment.

Apogee Therapeutics (NASDAQ: APGE) is a clinical-stage biopharmaceutical company developing a pipeline of next-generation, extended half-life (HLE) antibodies engineered to treat immunological and inflammatory diseases — with atopic dermatitis (AD) and asthma as its primary targets. The company's thesis is direct and compelling: take validated biological targets, engineer antibodies with dramatically longer half-lives, and deliver comparable or superior efficacy with a fraction of the injections required by existing therapies.

UroGen and Teva resolved the patent litigation around JELMYTO. The headline is legal, but the real investor story is broader: UroGen gets a clearer commercial window while ZUSDURI scales, and Teva secures future generic optionality while its larger turnaround story continues to shift toward innovative medicines, biosimilars and disciplined execution.